HUTCHMED (China) Limited (HCM)
NEUTRALFondamental
42
Prix
$12.28
Capitalisation boursière
$2.12B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$109M
12 derniers mois jusqu'au dernier trimestre publié — estimation à partir de ratios par action
Résultat net
$91M
12 derniers mois jusqu'au dernier trimestre publié — estimation à partir de ratios par action
Flux de trésorerie libre
$-19M
Capitaux propres totaux
$1.26B
Passif total
$95M
Ratio de liquidité général
5.64
Couverture des intérêts
-
Dette/EBITDA
-
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$8.56
Prix actuel
$12.28
Marge de sécurité
-43.4%
Fourchette de juste valeur
$5.56 - $11.56
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
23.26
ROE
1.5%
Ratio P/B
8.58
P/FCF
-
Marge brute
38.7%
ROIC
0.1%
Radar de rentabilité
Value Creation (Economic Moat)
ROIC
0.1%
WACC
10.4%
ROIC − WACC
-10.3 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critères d'analyse fondamentale
Réussi (8)
- Gross Margin 38.7%
- Debt/Equity ratio
- Current Ratio
- ROE 37.0%
- Revenue Growth 5Y 19.2%
- Analyst Consensus 85% Buy
- Earnings Surprise avg 95.6%
- Net Margin Trend 83.3% vs 6.0%
Échoué (9)
- Price CAGR -0.72%
- ROIC 0.1%
- P/B Ratio 8.58
- Operating Margin -7.1%
- Positive Free Cash Flow
- Price below Graham Number
- DCF valuation (Unknown)
- Earnings Quality (OCF/NI) 0.04
- Piotroski F-Score 1/9
Indisponible (10)
- EPS data insufficient
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- PEG Ratio (need PE > 0 and growth > 0)
- Share Dilution (missing shares data)
Score F de Piotroski
Préoccupations financières sérieuses
Qualité des bénéfices
Qualité faible : examiner la comptabilité
Dilution du capital
Rachat d'actions. Favorable aux actionnaires
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. Chig Fung Cheng BEc, CA | Acting CEO, CFO & Executive Director | 58 |
| Dr. Wei-Guo Su B.Sc., Ph.D. | CEO, Chief Scientific Officer & Executive Director (Leave of Absence) | 66 |
| Ms. Yiling Cui | Executive VP & Head of Operations | - |
| Dr. Xinhui Hu Ph.D. | Executive Vice President & Chief Technical Officer | 52 |
| Mr. David Ng | Head of Investor Relations & Capital Strategies | - |
| Mr. Charles George Rupert Nixon | Group General Counsel | 55 |
| Mr. Kin Hung Lee M.B.A. | Senior Vice President of Corporate Management & Communications | 48 |
| Ms. Selina Zhang | Senior Vice President of Global Human Resources | - |
| Dr. Qingmei Wang Ph.D. | Executive Vice President of Business Development & Strategic Alliances | 62 |
| Dr. Thomas Fu | Senior Vice President of Global Quality | - |
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Latest News
Recent headlines for HCM, sourced from Markets Gazette.